Search filters

List of works by Nicholas J. Vogelzang

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

scientific article published on 8 December 2016

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

scientific article published in September 2004

A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy

scientific article published on September 2008

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma

scientific article published in January 2004

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

scientific article published on 19 November 2020

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

scientific article published on 01 March 2011

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

scientific article published in October 2002

A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.

scientific article published in February 2009

A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?

scientific article published on February 2004

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma

scientific article

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma

scientific article published on 09 January 2019

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

scientific article published on 26 July 2017

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

scientific article

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

scientific article published on 05 April 2019

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

scientific article

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

scientific article

A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer

scientific article

A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors

scientific article published on 19 July 2008

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

scientific article published in November 2004

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

scientific article

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

scientific article

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

scientific article published in September 2008

A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy

scientific article

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

scientific article published on May 2002

A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer

scientific article

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

scientific article published on May 2004

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

scientific article published in March 2006

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

scientific article published on March 2006

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

scientific article published on 2 February 2017

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgro

scientific article

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study ⬇️

scientific article published on September 18, 2012

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

scientific article

Activities and accomplishments of the cancer and leukemia group B genitourinary committee.

scientific article

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

scientific article published on July 16, 2012

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study ⬇️

scientific article published on April 18, 2011

Adjuvant Androgen-Deprivation Therapy for Prostate Cancer: Should Docetaxel Be Added?

scientific article published on 01 May 2019

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

scientific article published in April 2007

Advanced Prostate Cancer 2010: What a Year! ⬇️

scientific article published on 01 December 2010

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

scientific article published in April 2002

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

scientific article

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

scientific article published on 2 November 2015

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

scientific article

Another Step Toward the Cure of Metastatic Renal Cell Carcinoma? ⬇️

scientific article published on October 25, 2010

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

scientific article published in August 2015

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

scientific article published in March 2004

Antiangiogenic Agents, Chemotherapy, and the Treatment of Metastatic Transitional Cell Carcinoma ⬇️

scientific article published on January 22, 2013

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.

scientific article published in January 2017

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.

scientific article published on 8 February 2018

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

scientific article published on 18 December 2017

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

scientific article published on 01 May 2020

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

scientific article published on 4 November 2015

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

scientific article published on 27 May 2016

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

scientific article published on 25 October 2013

Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

article published in 1995

Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?

scientific article published on 28 September 2018

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

article

CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer

scientific article

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

scientific article

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

scientific article published on 04 December 2018

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial ⬇️

scientific article published on November 19, 2012

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

scientific article published on 28 February 2019

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

scientific article

Call for revision of College of American Pathologists-mandated requirements for retention of laboratory records and materials

scientific article published on 01 November 2008

Cancer in Nevada's adolescent and young adult population

scientific article published on 01 March 2008

Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management

scientific article published on 22 February 2016

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

scientific article published on 8 March 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

scientific article

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

scientific article published on 31 January 2018

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

scientific article published on 23 March 2016

Chemotherapy for malignant pleural mesothelioma

scientific article published on 01 May 2008

Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer ⬇️

scientific article published on June 25, 2011

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer

scientific article published on 10 August 2016

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.

scientific article published on 6 November 2017

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

scientific article

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial

scientific article

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

scientific article

Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial

scientific article published in April 2003

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

scientific article

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

scientific article published on 29 January 2018

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

scientific article published on 26 October 2017

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

scientific article

Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology

scientific article

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology

scientific article published on 3 December 2012

Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies

scientific article published on 01 July 2006

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review

scientific article

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States

scientific article published on 27 August 2014

Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer ⬇️

scientific article published on July 1, 2011

Conclusion and future directions.

scientific article

Conditional Survival in de novo Metastatic Urothelial Carcinoma

scientific article published on 26 August 2015

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

article

Current vaccination strategies for prostate cancer

scientific article published on 03 October 2011

Development and validation of a scale to measure disease-related symptoms of kidney cancer

scientific article

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) ⬇️

scientific article published on November 24, 2010

Do patients with metastatic renal cell carcinoma benefit from sunitinib?

scientific article published on 01 February 2007

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

scientific article

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

scientific article

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 3 March 2015

Does PC-SPEs interact with warfarin?

scientific article published in April 2002

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

scientific article published in January 2002

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

scientific article published in July 2004

Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices

scientific article

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

scientific article published on 17 February 2014

Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate

scientific article published on 01 January 2010

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

scientific article published on 01 May 2018

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

scientific article published in February 2003

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

scientific article published on 5 December 2016

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

scientific article published on 13 May 2014

Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma

scientific article published on 24 May 2018

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort

scientific article published on 20 February 2014

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

scientific article

Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis

scientific article

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

scientific article

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

scientific article

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782

scientific article published on 16 December 2011

Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer

scientific article published on 01 April 2005

Emerging drugs for the treatment of metastatic renal cancer.

scientific article published on November 2007

Emerging insights into the biology and therapy of malignant mesothelioma

scientific article

Enzalutamide--a major advance in the treatment of metastatic prostate cancer.

scientific article

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details

scientific article

Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans

scientific article published in October 2005

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

scientific article published on 07 August 2019

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

scientific article published on 13 April 2017

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

scientific article published on 16 May 2014

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.

scientific article published on 15 November 2014

First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?

scientific article published on 19 July 2010

Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity

scientific article published on 01 May 2002

From the guest editors: the dramatic advances in the treatment of metastatic renal cancer that have occurred over the last 3 years, with an eye toward the potential future directions of the field

scientific article published on 01 September 2008

Future Challenges for Drug Development in Renal Cell Carcinoma

scientific article published on 19 December 2016

Future directions for gemcitabine in the treatment of genitourinary cancer

scientific article

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers

scientific article

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

scientific article published on 28 March 2018

Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention

scientific article

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial

scientific article

Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

scientific article

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition

scientific article

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

scientific article published on 07 April 2021

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC).

scientific article published on 4 November 2015

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

scientific article

Importance of serum hemoglobin in hormone refractory prostate cancer

scientific article published on 01 April 2002

In Reply

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma

scientific article

Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer ⬇️

scientific article published on 01 December 2010

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

scientific article published on 2 April 2007

Integrative tumor board: metastatic renal cell carcinoma: medical oncology

scientific article published on 01 March 2004

Intermittent versus continuous androgen deprivation in prostate cancer

scientific article published on April 2013

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.

scientific article

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma

scientific article

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

scientific article published on 25 March 2019

Long-term response in primary renal cancer to sequential antiangiogenic therapy

scientific article published on 10 August 2009

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

scientific article (publication date: 27 November 2014)

Malignant pleural mesothelioma

scientific article published on 01 May 2004

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.

scientific article published on July 2008

Managing Refractory Metastatic Renal Cell Carcinoma: A RECORD Spinning on a Tilted AXIS ⬇️

scientific article published on August 3, 2011

Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques

scientific article published in May 2004

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

scientific article

Metronomic chemotherapy: teaching old drugs new tricks?

scientific article published on 01 July 2004

Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers

scientific article published on 24 June 2016

Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.

scientific article published in August 2014

Monitoring response, prediction methodology, staging, and imaging in prostate cancer

scientific article published on 01 January 2006

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma

scientific article published on 13 April 2009

Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma ⬇️

scientific article published on June 4, 2012

Multimodality therapy in mesothelioma: role of chemotherapy

scientific article

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

article

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

scientific article

New agents in the management of advanced mesothelioma.

scientific article

New and promising strategies in the management of bladder cancer.

scientific article published on January 2015

Newer issues in mesothelioma chemotherapy.

scientific article published on February 2006

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

scientific article published on 15 May 2019

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

scientific article published on 21 February 2020

Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma

scientific article

Novel agents for the treatment of advanced kidney cancer.

scientific article

Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease

scientific article published on 06 April 2010

Outcomes and prognosis in advanced renal cell carcinoma

scientific article published on June 2007

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy

scientific article

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

scientific article

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

scientific article

PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward

scientific article published on 14 July 2014

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study

scientific article published on 19 November 2019

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

scientific article published on May 2008

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

scientific article published on 27 November 2017

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

scientific article published on 14 August 2020

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.

scientific article published on 2 March 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

scientific article published on 17 February 2017

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

scientific article published on 17 February 2007

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer

scientific article published on 20 January 2019

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors ⬇️

scientific article published on January 10, 2011

Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days ⬇️

scientific article published on May 1, 2003

Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).

scientific article

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action

scientific article

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

scientific article

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

scientific article published on 01 January 2005

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

scientific article published on 06 August 2019

Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032

scientific article

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

scientific article published on 20 October 2017

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

scientific article published on 3 August 2009

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

scientific article

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

scientific article

Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer

scientific article published on 01 September 2006

Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma

scientific article

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

scientific article published on 06 April 2018

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

scientific article published on 28 February 2019

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

scientific article published in January 2007

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

scientific article

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

scientific article published on March 2004

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma

scientific article published on 23 March 2018

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study

scientific article

Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease.

scientific article published on 12 November 2013

Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480

scientific article published on 01 March 2006

Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States

scientific article published on 12 March 2015

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

scientific article published in October 2003

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

scientific article published in April 2003

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

scientific article published in August 2005

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.

scientific article

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies

scientific article published on 31 January 2020

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

scientific article published on 20 April 2009

Promising systemic therapy for renal cell carcinoma

scientific article

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

scientific article

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

scientific article

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

scientific article

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

scientific article published on 26 June 2017

Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.

scientific article

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

scientific article published on 03 March 2014

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

scientific article published in August 2002

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

scientific article published on 13 June 2016

Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma

scientific article

Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma

scientific article

Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer

scientific article published on 13 December 2019

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data

scientific article published on 01 June 2018

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews

scientific article published on 19 November 2015

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis

scientific article published on 5 January 2017

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma

scientific article published on 16 October 2019

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era

scientific article published in 2023

Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.

scientific article

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer

scientific article published on 04 September 2019

Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data

scientific article published on 10 March 2020

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

scientific article published in April 2008

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma

scientific article published on 24 October 2018

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

scientific article published on 14 August 2020

SECONDARY HORMONAL MANIPULATIONS IN THE TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCER

scientific article (publication date: 24 November 2010)

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer

scientific article published on 6 April 2015

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

scientific article published on 16 February 2022

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

scientific article published on 14 June 2020

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

scientific article published on 16 May 2020

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer

scientific article published in February 2004

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

scientific article published on 21 June 2004

Second-line chemotherapy for advanced hormone-refractory prostate cancer

scientific article published on February 2008

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

scientific article published on 25 May 2010

Selecting a secondary treatment ⬇️

scientific article published on May 1, 2003

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

scientific article published on 10 November 2016

Sequential Therapy in Metastatic Renal Cell Carcinoma

scientific article published on 5 April 2016

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

scientific article published on 24 February 2014

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

scientific article published on 20 December 2017

Signal-transduction inhibitors in renal cell carcinoma

scientific article published on May 2007

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma

scientific article published on 28 September 2013

Standard therapy for the treatment of malignant pleural mesothelioma

scientific article

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma

scientific article published on 16 February 2010

Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid

scientific article published on 01 July 2007

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

scientific article published on 01 March 2003

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

scientific article published on 28 February 2020

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

scientific article published on 13 February 2020

Systemic therapy for metastatic urothelial carcinoma

scientific article published on 05 December 2007

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

scientific article published on 11 November 2009

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

scientific article

The emerging role of antifolates in the treatment of malignant pleural mesothelioma

scientific article

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials

scientific article published on 01 February 2007

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

scientific article

There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.

scientific article published on September 2015

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

scientific article

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

scientific article

Treatment options in metastatic renal carcinoma: an embarrassment of riches

scientific article published on 5 December 2005

Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices

scientific article published on 09 July 2014

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

scientific article

Two paths forward in metastatic castration-resistant prostate cancer.

scientific article published in July 2013

Use of Testosterone Replacement Therapy in Patients with Prostate Cancer ⬇️

scientific article published on June 1, 2011

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

scientific article published on 10 May 2017

Variability in mesothelioma tumor response classification.

scientific article published in April 2006

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity

scientific article

Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, et al. J Clin Oncol 2008;26:4563-71

scientific article published on 01 July 2009

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

scientific article

Paulina is supported by:

About Paulina

Help